



MSD ONCOLOGY POLICY GRANT PROGRAM

For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world.

MSD Oncology is extending an open invitation to the Australian research community to participate in the MSD Oncology Grant Program. The grant aims to establish a global community of health policy researchers driving evidence-based and forward-looking health policy recommendations that will improve health outcomes for cancer patients. This competitive grant will be issued publicly and will be for research projects aimed at analysing policy and health system readiness to deliver sustainable and innovative cancer care.

To be eligible for participation in the MSD Oncology Grant Program, researchers and research teams must meet the following selection criteria:

- Come from an accredited local and/or regional academic public institution
- Have a proven track record in research in the cancer space
- Have experience working in and researching health policy
- Demonstrate ability to publish a quality, peer-reviewed publication within one year

If you would like to participate, please send a brief, one-page response to darin.kottege@merck.com for more information. This response should describe your interest in the program and your ability to meet the above selection criteria.